Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
Status:
Completed
Trial end date:
2017-07-30
Target enrollment:
Participant gender:
Summary
To determine the safety, tolerability, pharmacokinetics, maximum tolerated dose, and
recommended Phase II dose of BAY1143572 in a once-daily or an intermittent dosing schedule in
subjects with advanced acute leukemia